Latest news with #DrugDevelopment
Globe and Mail
07-08-2025
- Business
- Globe and Mail
Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Pulmonary Fibrosis Pipeline Insight 2025' report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook Key Takeaways from the Pulmonary Fibrosis Pipeline Report In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo. In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis. DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment. The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs Pulmonary Fibrosis Emerging Drugs Profile BMS-986278: Bristol-Myers Squibb BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis. AK3280: Ark Biosciences Inc. AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. LYT-100: PureTech Health LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. ARO-MMP7: Sarepta Therapeutics ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. TRK-250: Toray Industries, Inc TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. The Pulmonary Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment. Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs Pulmonary Fibrosis Companies Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Pulmonary Fibrosis Products have been categorized under various Molecule types such as Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers Scope of the Pulmonary Fibrosis Pipeline Report Coverage- Global Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Pulmonary Fibrosis: Overview Therapeutic Assessment Pulmonary Fibrosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) BMS-986278: Bristol-Myers Squibb Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK3280: Ark Biosciences Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products RSBT 001: RS BioTherapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Fibrosis Key Companies Pulmonary Fibrosis Key Products Pulmonary Fibrosis- Unmet Needs Pulmonary Fibrosis- Market Drivers and Barriers Pulmonary Fibrosis- Future Perspectives and Conclusion Pulmonary Fibrosis Analyst Views Pulmonary Fibrosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
05-08-2025
- Business
- Globe and Mail
RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' RIPK1 Inhibitor Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market. The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the RIPK1 Inhibitor Pipeline Report: Companies across the globe are diligently working toward developing novel RIPK1 Inhibitor treatment therapies with a considerable amount of success over the years. RIPK1 Inhibitor Key players such as - Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others, are developing therapies for the RIPK1 Inhibitor treatment RIPK1 Inhibitor Emerging therapies such as - SAR443122, GFH312, R552, and others are expected to have a significant impact on the RIPK1 Inhibitor market in the coming years. In May 2025, Accropeutics' investigational drug has successfully met the primary objectives in a Phase 2 clinical trial for psoriasis conducted in China, leading the company to commit to accelerating the clinical advancement of its TYK2/JAK1 inhibitor, AC-201. In the trial, 145 Chinese patients with moderate to severe plaque psoriasis were administered one of three doses of AC-201 or a placebo. All dosing groups achieved the primary endpoint, with a significantly higher proportion of patients reaching a 75% improvement in their Psoriasis Area and Severity Score (PASI 75) at Week 12 compared to the placebo group. In October 2024, Sanofi discontinued its Phase 2 clinical trial of oditrasertib, an experimental RIPK1 inhibitor, in patients with relapsing and progressive multiple sclerosis (MS) after the treatment did not achieve its primary objectives. Initiated early last year, the trial failed to demonstrate a significant reduction in neurofilament light chain (NfL) levels — a biomarker associated with neurodegeneration. Additionally, the therapy did not meet any major secondary endpoints, as noted in a recent SEC filing by Denali Therapeutics, Sanofi's development partner. RIPK1 Inhibitor Overview A RIPK1 inhibitor is a type of drug that blocks the activity of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) — an enzyme involved in regulating inflammation, cell death (especially necroptosis), and immune responses. Overactivation of RIPK1 has been linked to several diseases, including autoimmune disorders, neurodegenerative conditions, and inflammatory diseases. By inhibiting RIPK1, these drugs aim to reduce excessive inflammation and tissue damage, offering a promising therapeutic strategy for conditions like multiple sclerosis, Alzheimer's disease, and psoriasis. Emerging RIPK1 Inhibitor Drugs Under Different Phases of Clinical Development Include: RIPK1 Inhibitor Pipeline Therapeutics Assessment RIPK1 Inhibitor Assessment by Product Type RIPK1 Inhibitor By Stage and Product Type RIPK1 Inhibitor Assessment by Route of Administration RIPK1 Inhibitor By Stage and Route of Administration RIPK1 Inhibitor Assessment by Molecule Type RIPK1 Inhibitor by Stage and Molecule Type DelveInsight's RIPK1 Inhibitor Report covers around 12+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Download Sample PDF Report to know more about RIPK1 Inhibitor drugs and therapies RIPK1 Inhibitor Pipeline Analysis: The RIPK1 Inhibitor pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the RIPK1 Inhibitor treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment. RIPK1 Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Scope of RIPK1 Inhibitor Pipeline Drug Insight Table of Contents 1 RIPK1 Inhibitor Report Introduction 2 RIPK1 Inhibitor Executive Summary 3 RIPK1 Inhibitor Overview 4 RIPK1 Inhibitor- Analytical Perspective In-depth Commercial Assessment 5 RIPK1 Inhibitor Pipeline Therapeutics 6 RIPK1 Inhibitor Late Stage Products (Phase II/III) 7 RIPK1 Inhibitor Mid Stage Products (Phase II) 8 RIPK1 Inhibitor Early Stage Products (Phase I) 9 RIPK1 Inhibitor Preclinical Stage Products 10 RIPK1 Inhibitor Therapeutics Assessment 11 RIPK1 Inhibitor Inactive Products 12 Company-University Collaborations (Licensing/Partnering) Analysis 13 RIPK1 Inhibitor Key Companies 14 RIPK1 Inhibitor Key Products 15 RIPK1 Inhibitor Unmet Needs 16 RIPK1 Inhibitor Market Drivers and Barriers 17 RIPK1 Inhibitor Future Perspectives and Conclusion 18 RIPK1 Inhibitor Analyst Views 19 Appendix 20 About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
04-08-2025
- Business
- Yahoo
Waters raises lower end of 2025 profit forecast on demand for lab equipment
(Reuters) -Lab equipment maker Waters raised the lower end of its annual profit forecast on Monday after reporting better-than-expected second-quarter results on improved demand from biotech clients for its tools used in drug development and research. Shares of the Milford, Massachusetts-based company were up 3.7% premarket in low trading volumes. The company supplies lab equipment and technology across the world, with the majority of its revenue coming from biopharma clients who use its tools for research and drug development. Last month, larger peer Thermo Fisher also raised the lower end of its annual profit forecast on strong demand for its products used in drug development. Waters forecast annual adjusted profit per share in the range of $12.95 to $13.05, compared with previously projected adjusted profit between $12.75 and $13.05. CEO Udit Batra said the forecast raise was partly driven by "strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s, PFAS and generics." Last month, Waters entered a deal to buy a bioscience and diagnostics unit spun off from medtech provider Becton Dickinson, expanding its scale in clinical and diagnostic applications. Batra said the combination will also help extend the company's reach into resilient, high-volume end markets. Waters expects third-quarter adjusted profit per share in the range of $3.15 to $3.25, compared with analysts' average expectations of $3.23, according to data compiled by LSEG. The company reported second-quarter adjusted profit per share of $2.95, compared with analysts' estimates of $2.94. Its second-quarter revenue rose 9% to $771.3 million, compared with analysts' estimate of $748.7 million. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
04-08-2025
- Business
- Reuters
Waters raises lower end of 2025 profit forecast on demand for lab equipment
Aug 4 (Reuters) - Lab equipment maker Waters (WAT.N), opens new tab raised the lower end of its annual profit forecast on Monday after reporting better-than-expected second-quarter results on improved demand from biotech clients for its tools used in drug development and research. Shares of the Milford, Massachusetts-based company were up 3.7% premarket in low trading volumes. The company supplies lab equipment and technology across the world, with the majority of its revenue coming from biopharma clients who use its tools for research and drug development. Last month, larger peer Thermo Fisher (TMO.N), opens new tab also raised the lower end of its annual profit forecast on strong demand for its products used in drug development. Waters forecast annual adjusted profit per share in the range of $12.95 to $13.05, compared with previously projected adjusted profit between $12.75 and $13.05. CEO Udit Batra said the forecast raise was partly driven by "strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s, PFAS and generics." Last month, Waters entered a deal to buy a bioscience and diagnostics unit spun off from medtech provider Becton Dickinson (BDX.N), opens new tab, expanding its scale in clinical and diagnostic applications. Batra said the combination will also help extend the company's reach into resilient, high-volume end markets. Waters expects third-quarter adjusted profit per share in the range of $3.15 to $3.25, compared with analysts' average expectations of $3.23, according to data compiled by LSEG. The company reported second-quarter adjusted profit per share of $2.95, compared with analysts' estimates of $2.94. Its second-quarter revenue rose 9% to $771.3 million, compared with analysts' estimate of $748.7 million.
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
DelveInsight's, ' Glioma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Glioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Glioma Pipeline Outlook Key Takeaways from the Glioma Pipeline Report In July 2025, Eli Lilly and Company announced a study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. In July 2025, Istari Oncology Inc. announced a Phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of lerapolturev in recurrent WHO grade IV malignant glioma. In July 2025, Incyte Corporation conducted a study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal. In July 2025, Nuvation Bio Inc. organized a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment. The leading Glioma Companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Promising Glioma Pipeline Therapies such as DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Stay ahead with the most recent pipeline outlook for Glioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Glioma Treatment Drugs Glioma Emerging Drugs Profile AV-GBM-1: Aivita Biomedical, Inc. AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma. DB 107: Denovo BioPharma Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. MDNA55: Medicenna Therapeutics, Inc. MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma. Abemaciclib: Eli Lilly and Company Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. NMS-03305293: Nerviano Medical Sciences NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma. CAN-3110: Candel Therapeutics CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma. MB-101: Mustang Bio MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma. The Glioma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment. Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market Explore groundbreaking therapies and clinical trials in the Glioma Pipeline. Access DelveInsight's detailed report now! @ New Glioma Drugs Glioma Companies CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Glioma Products have been categorized under various Molecule types, such as Oligonucleotide Peptide Small molecule Unveil the future of Glioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Glioma Market Drivers and Barriers Scope of the Glioma Pipeline Report Coverage- Global Glioma Companies- CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others. Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others. Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Glioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Glioma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Glioma Disease: Overview Pipeline Therapeutics Therapeutic Assessment Glioma Disease– DelveInsight's Analytical Perspective Late Stage Products (Phase III) AV-GBM-1: Aivita Biomedical, Inc. Drug profiles in the detailed report….. Mid Stage Products (Phase II) DB 107: Denovo BioPharma Drug profiles in the detailed report….. Early Stage Products (Phase I) MB-101: Mustang Bio Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Glioma Disease Key Companies Glioma Disease Key Products Glioma Disease- Unmet Needs Glioma Disease- Market Drivers and Barriers Glioma Disease- Future Perspectives and Conclusion Glioma Disease Analyst Views Glioma Disease Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
